Defense Threat Reduction Agency

CONSTANT Is Honored To Be Ranked on the Inc. 5000 List!

Retrieved on: 
금요일, 8월 25, 2023
Federal Emergency Management Agency, U.S. Department of the Interior, Office of Inspector General, Office of Inspector General, U.S. Department of Health and Human Services, WA, Defense Threat Reduction Agency, PUD No. 1 of Jefferson County v. Washington Department of Ecology, Cal, DTRA, Privately held company, Associate, Emergency service, DOI, FEMA, Interior, Growth, Retail, Nursing

TORRANCE, Calif., Aug. 25, 2023 /PRNewswire-PRWeb/ -- Inc. Magazine released its annual list of the fastest-growing private companies in America. With three-year revenue growth of 181%, CONSTANT is thrilled to announce that we rank no. 2,908 among America's Fastest-Growing Private Companies.

Key Points: 
  • Constant and Associates, Inc. (CONSTANT) has been featured on the Inc. 5000 list as one of America's fastest growing companies.
  • With three-year revenue growth of 181%, CONSTANT is thrilled to announce that we rank no.
  • "We are honored to be recognized on the Inc. 5000 list," said Michelle Constant , Chief Executive Officer of CONSTANT.
  • We are proud that the Inc. 5000 recognition reflects the hard work and passion of CONSTANT and the trust of our clients.

Appili Therapeutics Reports Financial and Operational Results for First Quarter of Fiscal Year 2024

Retrieved on: 
금요일, 8월 11, 2023
Biotechnology, General Health, Pharmaceutical, Health, Patent, Air force academy, Partnership, PRV, Drug development, Technology transfer, U.S. Department of Defense Strategy for Operating in Cyberspace, Pharming, Bank statement, United States Patent and Trademark Office, International Accounting Standards Board, New Drug Application, Defense Threat Reduction Agency, NDA, Infection, United States Air Force Academy, Research, Government, Metronidazole, DOD, Investigational New Drug, Non-governmental organization, Indian stock exchange, PDUFA, The Last of Us Part I, TSX, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, IND, Therapy, Food, Pharmaceutical industry, Security (finance), USAFA, Tularemia

Appili Therapeutics Inc. (TSX:APLI; OTCQB: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and biodefense products, today announced its financial and operational results for the first quarter of its fiscal year 2024, which ended on June 30, 2023.

Key Points: 
  • Appili Therapeutics Inc. (TSX:APLI; OTCQB: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and biodefense products, today announced its financial and operational results for the first quarter of its fiscal year 2024, which ended on June 30, 2023.
  • These achievements are expected to position us with the required resources to continue to make progress in advancing our infectious disease assets."
  • On May 5, 2023, Appili executed an initial cooperative agreement with USAFA the previously announced funding of the ATI-1701 program.
  • This initial funding, in the amount of US$7.3 million, will be used to kick-off ATI-1701 early-stage development and regulatory activities.

Defense Threat Reduction Agency Awards Valiant $18M Task Order to Provide Advance Cyber Support and Operations to Department of Defense Assessment Team

Retrieved on: 
수요일, 8월 9, 2023
Valiant, Mission assurance, U.S. Department of Defense Strategy for Operating in Cyberspace, Defense Threat Reduction Agency, DOD, Growth, DTRA, Fort Belvoir, Risk management

HERNDON, Va., Aug. 09, 2023 (GLOBE NEWSWIRE) -- Valiant announced today that it has been awarded an $18 million task order by the Defense Threat Reduction Agency (DTRA) to provide Advance Cyber support and operations at Fort Belvoir, VA, and other locations.

Key Points: 
  • HERNDON, Va., Aug. 09, 2023 (GLOBE NEWSWIRE) -- Valiant announced today that it has been awarded an $18 million task order by the Defense Threat Reduction Agency (DTRA) to provide Advance Cyber support and operations at Fort Belvoir, VA, and other locations.
  • This two-year task order falls under the Nuclear Enterprise Support Directorate's Mission Assurance program.
  • As part of this program, Valiant's team will conduct threat-emulative cyber assessments to support the objectives of the Department of Defense (DOD).
  • Valiant’s support will include cyber assessments, planning and coordination of cyber operations, development of code, tools, and exploits, and documentation management.

Parsons Reports Strong Second Quarter 2023 Results

Retrieved on: 
수요일, 8월 2, 2023
Maintenance (technical), General Services Administration, Small business, National Aeronautic Association, Chemical Weapons Convention, John F. Kennedy International Airport, Infrastructure Investment and Jobs Act, Defense, Engineering, United States Cyber Command, IDIQ, United States Department of Defense, Defense Threat Reduction Agency, Assessment, Port, Woman, GHG, Veteran, American City Business Journals, FAA, Critical infrastructure, EBITDA, Greenhouse gas, NASA, M55, U.S. Department of Defense Strategy for Operating in Cyberspace, Diversity, Growth, ESG, Ambition, Transport, Port Authority of New York and New Jersey, Federal Aviation Administration, Video game, Construction, Arms industry, Renewable energy, Maintenance, D.C

CENTREVILLE, Va., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Parsons Corporation (NYSE: PSN) today announced financial results for the second quarter ended June 30, 2023.

Key Points: 
  • Second quarter 2023 adjusted EBITDA including noncontrolling interests increased by $3 million, or 10%, compared to the prior year period.
  • Cash flow from operating activities: Second quarter 2023: $23 million compared to $51 million in second quarter of 2022.
  • During the second quarter of 2023, the company won six single-award contracts worth more than $100 million each, a company record.
  • In addition, the company won an additional $100 million contract after the 2023 second quarter ended.

VitriVax Awarded $29M DoD Contract to Fund Vaccine Research

Retrieved on: 
수요일, 7월 19, 2023
Other Defense, Health Technology, Contracts, White House, Federal Government, University, Pharmaceutical, Education, General Health, Defense, Infectious Diseases, Public Policy, Government, Science, Biotechnology, Health, Research, Vaccine, Good, Latham, Good manufacturing practice, U.S. Department of Defense Strategy for Operating in Cyberspace, Principal investigator, New Drug Application, Defense Threat Reduction Agency, Glanders, Melioidosis, DTRA, Military personnel, Reno 1868 FC, Disease, Operation

VitriVax Inc., a formulation technology company, has been awarded a $29M five-year contract by the Defense Threat Reduction Agency (DTRA), an agency within the U.S. Department of Defense.

Key Points: 
  • VitriVax Inc., a formulation technology company, has been awarded a $29M five-year contract by the Defense Threat Reduction Agency (DTRA), an agency within the U.S. Department of Defense.
  • The project will focus on preclinical studies and development of Good Manufacturing Practice protocols, working toward an Investigational New Drug Application submission.
  • VitriVax has built a strong research team consisting of formulation and analytical scientists, as well as particle engineers and manufacturing experts.
  • They have strategically partnered with the University of Nevada, Reno and the Latham BioPharm Group, Inc., to compile a support team of industry veterans with years of Bp vaccine development, government program management experience, and government contract compliance knowledge.

Parsons Awarded $170M Defense Threat Reduction Agency Task Order

Retrieved on: 
수요일, 7월 12, 2023
Weapon, Parsons Corporation, Defense Threat Reduction Agency, Assessment, Parsons, DTRA, Organization, DOD, Engineering, College of Engineering (KNUST), PSN, NYSE, Department of Defence, WMD, Arms industry

CENTREVILLE, Va., July 12, 2023 (GLOBE NEWSWIRE) -- Parsons Corporation (NYSE: PSN) announced today that the company was awarded a task order by the Defense Threat Reduction Agency (DTRA) under the Assessments, Exercises, Modeling, and Simulation Support indefinite-delivery, indefinite-quantity multiple award task order contract.

Key Points: 
  • CENTREVILLE, Va., July 12, 2023 (GLOBE NEWSWIRE) -- Parsons Corporation (NYSE: PSN) announced today that the company was awarded a task order by the Defense Threat Reduction Agency (DTRA) under the Assessments, Exercises, Modeling, and Simulation Support indefinite-delivery, indefinite-quantity multiple award task order contract.
  • The $170 million ceiling value task order to provide continued support to the agency consists of a one-year base period and four one-year option periods under the company’s Federal Solutions segment and includes existing and new work for the company.
  • Under this task order, Parsons will conduct vulnerability assessments, technical support projects, design reviews, and analyses in support of Department of Defense (DOD) and DTRA efforts; task order work also includes support to DTRA’s Nuclear Enterprise Directorate operational programs.
  • “Parsons is a trusted partner and security solutions provider to organizations around the globe,” said Jon Moretta, president, Engineered Systems, for Parsons.

Appili Therapeutics Reports Fiscal Year 2023 Financial and Operational Results

Retrieved on: 
금요일, 6월 23, 2023
Infectious Diseases, Biotechnology, Pharmaceutical, Health, Taste, Pharming, Social stigma, Defense Threat Reduction Agency, Patent, Patient, Government, R, Ulcer, International Accounting Standards Board, U.S. Department of Defense Strategy for Operating in Cyberspace, Infection, Research, Net, SEDAR, TSX, FDA, Skin, Delays, Cutaneous leishmaniasis, United States Patent and Trademark Office, Scar, Parasitism, Metronidazole, DOD, Non-governmental organization, Fast track (FDA), The Last of Us Part I, Therapy, Accounting, Partnership, PRV, Drug development, Bank statement, USAFA, NDA, United States Air Force Academy, Sale, State, Indian stock exchange, Anthrax, Pharmaceutical industry, Cryptocurrency, Tularemia, IND

Appili Therapeutics Inc. (TSX:APLI; OTCQB: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and biodefense products, today announced its financial and operational results for the fiscal year ended March 31, 2023, and provided an update on the Company’s strategy for fiscal 2024.

Key Points: 
  • Appili Therapeutics Inc. (TSX:APLI; OTCQB: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and biodefense products, today announced its financial and operational results for the fiscal year ended March 31, 2023, and provided an update on the Company’s strategy for fiscal 2024.
  • In May 2023, Appili executed the initial contract with USAFA (the “USAFA Cooperative Agreement”) for the previously announced funding of the ATI-1701 program.
  • Appili has submitted its first invoice for such costs and anticipates receiving payment by the end of June 2023.
  • The Company has included a going concern note in its financial statements for the fiscal year ended March 31, 2023.

DoD partners with Detect-Ion to develop Point-of-Care Breath Diagnostics for Early Detection of Infected Warfighters

Retrieved on: 
화요일, 6월 6, 2023
Infection, POC, Human, Defense Innovation Unit, Oxygen, United States Department of Defense, COVID-19, Carbon dioxide, Organic compound, Airport, Intelligence, CLARION, Volatile organic compound, VOC, Biomarker, DTRA, Innovation Unit, Science, Argon, Defense Threat Reduction Agency, DARPA, Carbon monoxide, Hospital, Investment, Algorithm, Breath diagnostics, IVD, Nitrogen, PCR, IARPA, Medical imaging

TAMPA, Fla., June 6, 2023 /PRNewswire/ --The recent COVID-19 pandemic has highlighted the need to rapidly detect infected humans to intervene early before severe conditions develop and to mitigate the spread of infections across a larger population. The ideal diagnostics approach should be painless (non-invasive), rapid, cost-effective, accurate, and should be versatile to detect multiple infectious pathogens, in some cases pre-symptomatically (even before the symptoms are visible). This diagnostics capability when applied to United States Department of Defense (DoD) warfighters would ensure mission readiness in austere environments, where providing adequate medical personnel and/or traditional diagnostics labs can be challenging. With this vision, DoD's DIU teamed up with DTRA and has awarded an Other Transaction (OT) contract to Detect-Ion to develop such a Point-of-Care (PoC) Breath Diagnostics.

Key Points: 
  • This diagnostics capability when applied to United States Department of Defense (DoD) warfighters would ensure mission readiness in austere environments, where providing adequate medical personnel and/or traditional diagnostics labs can be challenging.
  • With this vision, DoD's DIU teamed up with DTRA and has awarded an Other Transaction (OT) contract to Detect-Ion to develop such a Point-of-Care (PoC) Breath Diagnostics.
  • CLARION in-vitro diagnostics (IVD) may offer sufficient versatility to potentially screen against multiple infection types in a single breath test.
  • The project is planned over three years and allows DoD to pursue follow-on production if the pilot project succeeds in addressing the program metrics.

Virpax Pharmaceuticals To Present at Upcoming CB Tech Watch Seminar

Retrieved on: 
수요일, 5월 10, 2023
Other Health, Finance, Pharmaceutical, Surgery, Practice Management, Professional Services, General Health, Medical Devices, Infectious Diseases, Hospitals, Science, Biotechnology, Veterinary, Other Science, Health, DARPA, Central nervous system, Army, Defense Threat Reduction Agency, Federal, DTRA, CNS, DOD, Daubert v. Merrell Dow Pharmaceuticals, Inc., Post-traumatic stress disorder, Navy, Pain management, MET, Vaccine

Virpax® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ: VRPX), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and viral barrier indications, today announced that it has been invited to present its Molecular Envelope Technology (MET), as well as its AnQlarTM product candidate for viral inhibition that utilizes MET, at the June 8, 2023, virtual CB Tech Watch Seminar.

Key Points: 
  • Virpax® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ: VRPX), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and viral barrier indications, today announced that it has been invited to present its Molecular Envelope Technology (MET), as well as its AnQlarTM product candidate for viral inhibition that utilizes MET, at the June 8, 2023, virtual CB Tech Watch Seminar.
  • Mr. Anthony P. Mack, Chairman and CEO of Virpax, and Dr. Sheila A. Mathias, Chief Scientific Officer of Virpax will present on the Company’s behalf.
  • CB Tech Watch Seminar is a forum for companies to highlight their science and technology to the technical staff at the Defense Threat Reduction Agency (DTRA), Defense Advanced Research Projects Agency (DARPA) in addition to members of the Army, Navy and other military branches and Federal agencies.
  • “We are pleased to be invited to present at this seminar and have the opportunity to showcase our MET delivery platform to DTRA as well as other parts of the DOD and Federal technical experts.

PharmaJet Announces U.S. Government Award Expansion to Clinically Assess a DNA Vaccine Combined with its Systems

Retrieved on: 
화요일, 4월 18, 2023
Biotechnology, Medical Devices, Infectious Diseases, Health, Pharmaceutical, Stratis, Injection, United States Army Medical Research Institute of Infectious Diseases, DNA, Human, Partnership, Use, Alphavirus, U.S. Department of Defense Strategy for Operating in Cyberspace, USAMRIID, Licensure, Venezuelan equine encephalitis virus, DTRA, ID, Epidemic, Investigational New Drug, PDS, CGMP, Mortality, NHP, Defense Threat Reduction Agency, Encephalitis, IND, Infection, Pharmaceutical industry, Vaccine

The expansion award, worth over $4 million, will be used to further advance the clinical assessment of its Venezuelan Equine Encephalitis Virus (VEEV) DNA candidate vaccine in combination with either Tropis Intradermal (ID) or Stratis Intramuscular (IM) Systems.

Key Points: 
  • The expansion award, worth over $4 million, will be used to further advance the clinical assessment of its Venezuelan Equine Encephalitis Virus (VEEV) DNA candidate vaccine in combination with either Tropis Intradermal (ID) or Stratis Intramuscular (IM) Systems.
  • Venezuelan Equine Encephalitis Virus is an alphavirus that causes encephalitis and potential mortality in infected humans and equines.
  • It is listed as a potential biothreat agent with no approved human vaccine or therapeutic currently available.
  • PharmaJet is working with a contract manufacturer to produce the cGMP VEEV plasmid DNA vaccine and is preparing the Investigational New Drug (IND) application.